申请人:Galley Guido
公开号:US09029370B2
公开(公告)日:2015-05-12
The present invention relates to compounds of formula
wherein R1, R2, R3, X, Z, Ar, and n are as described in the claims,
Ar is phenyl or heteroaryl, selected from the group consisting of 1H-indazole-3yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, pyrimidine-5-yl, 1H-pyrazole-3-yl, 1H-pyrazole-4-yl and 1H-pyrazole-5-yl;
or to a pharmaceutically suitable acid addition salt thereof, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
本发明涉及式中的化合物,其中R1,R2,R3,X,Z,Ar和n如权利要求所述,Ar为苯基或杂环芳基,所选自1H-
吲唑-3基,
吡啶-2基,
吡啶-3基,
吡啶-4基,
嘧啶-5基,1H-
吡唑-3基,1H-
吡唑-4基和1H-
吡唑-5基;或其药学上适宜的酸加盐,可用于治疗抑郁症,焦虑症,双相情感障碍,注意力缺陷多动障碍(ADHD),应激相关障碍,精神障碍,精神分裂症,神经系统疾病,帕
金森病,神经退行性疾病,阿尔茨海默病,癫痫,偏头痛,高血压,物质滥用,代谢紊乱,进食障碍,糖尿病,糖尿病并发症,肥胖症,血脂异常,能量消耗和吸收障碍,体温稳态的障碍和功能障碍,睡眠和昼夜节律的障碍,以及心血管疾病的治疗。